CMSS1 (cms1 ribosomal small subunit homolog) is an RNA-binding protein that functions in post-transcriptional gene regulation with emerging roles in cancer pathogenesis. In non-small cell lung cancer, CMSS1 promotes tumor progression by binding to the 5' UTR of hTERT mRNA, stabilizing the transcript and enabling telomerase-mediated cell immortalization 1. CMSS1 is significantly upregulated across multiple malignancies including hepatocellular carcinoma, NSCLC, and diffuse large B-cell lymphoma, correlating with advanced disease stage and poor clinical outcomes [PMID:38160346; 2; 33]. High CMSS1 expression predicts reduced overall survival and disease-free survival in hepatocellular carcinoma patients 4. Mechanistically, CMSS1 regulates cell adhesion and interacts with other RNA-binding proteins including RBM34 and DDX5 to modulate hTERT expression 1. CMSS1 expression associates with immunosuppressive tumor microenvironments, negatively correlating with CD4+ T cell infiltration while positively correlating with macrophages and regulatory T cells 2. CMSS1 was also identified as a host factor maintaining HIV-1 latency in infected cells 5. These findings establish CMSS1 as a promising prognostic biomarker and potential therapeutic target for precision cancer medicine.